News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
OrthoLogic Corporation Announces Positive Safety Data for Initial AZX100 Phase 1 Human Clinical Trial in Dermal/Hypertrophic Scarring
May 8, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TEMPE, Ariz., May 8, 2008 (PRIME NEWSWIRE) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today the completion of dosing and patient follow-up for its initial AZX100 Phase 1 human clinical trial in dermal/hypertrophic scarring.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
MORE ON THIS TOPIC
Insights
The Italian inflection point: Clinical strength, culture and capital
August 13, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Rare diseases
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
August 12, 2026
·
3 min read
·
Annalee Armstrong
IPO
2026 IPO stock tracker: How newly public biotechs are performing
August 12, 2026
·
1 min read
·
Gabrielle Masson
Psychedelics
Definium’s LSD asset beats analyst expectations in Phase 3 anxiety readout
August 12, 2026
·
4 min read
·
Gabrielle Masson
